Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia

Jing Chen, Cynthia A. Pise-Masison, Joanna H. Shih, John C. Morris, John Edward Janik, Kevin C. Conlon, Anne Keating, Thomas A. Waldmann

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Adult T-cell leukemia (ATL) is an aggressive malignancy of CD4+CD25+ lymphocytes caused by human T-cell lymphotropic virus type 1. Currently, there is no accepted curative therapy for ATL. In gene expression profiling, the antiapoptotic protein survivin (BIRC5) demonstrated a striking increase in ATL, and its expression was increased in patient ATL cells resistant to the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H). In this study, we investigated the antitumor activity of a small-molecule survivin suppressant YM155 alone and in combination with alemtuzumab in a murine model of human ATL (MET-1). Both YM155 alone and its combination with alemtuzumab demonstrated therapeutic efficacy by lowering serum soluble IL-2Rα (sIL-2Rα) levels (P < .001) and prolonged the survival of tumor-bearing mice (P < .0001). Moreover, the combination of YM155 with alemtuzumab demonstrated markedly additive antitumor activity by significantly lowering serum sIL-2Rα levels and improving the survival of leukemia-bearing mice compared with monotherapy with either YM155 (P < .001) or alemtuzumab (P < .05). More significantly, all mice that received the combination therapy survived and were tumor free >6 months after treatment. Our data support a clinical trial of the combination of YM155 with alemtuzumab in ATL.

Original languageEnglish (US)
Pages (from-to)2029-2037
Number of pages9
JournalBlood
Volume121
Issue number11
DOIs
StatePublished - Jan 1 2013

Fingerprint

Adult T Cell Leukemia Lymphoma
T-cells
Human T-lymphotropic virus 1
Gene Expression Profiling
Lymphocytes
alemtuzumab
Viruses
Gene expression
Therapeutics
Clinical Trials
T-Lymphocytes
Monoclonal Antibodies
Molecules
Serum
Neoplasms
Proteins

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Chen, J., Pise-Masison, C. A., Shih, J. H., Morris, J. C., Janik, J. E., Conlon, K. C., ... Waldmann, T. A. (2013). Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia. Blood, 121(11), 2029-2037. https://doi.org/10.1182/blood-2012-05-427773

Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia. / Chen, Jing; Pise-Masison, Cynthia A.; Shih, Joanna H.; Morris, John C.; Janik, John Edward; Conlon, Kevin C.; Keating, Anne; Waldmann, Thomas A.

In: Blood, Vol. 121, No. 11, 01.01.2013, p. 2029-2037.

Research output: Contribution to journalArticle

Chen, J, Pise-Masison, CA, Shih, JH, Morris, JC, Janik, JE, Conlon, KC, Keating, A & Waldmann, TA 2013, 'Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia', Blood, vol. 121, no. 11, pp. 2029-2037. https://doi.org/10.1182/blood-2012-05-427773
Chen, Jing ; Pise-Masison, Cynthia A. ; Shih, Joanna H. ; Morris, John C. ; Janik, John Edward ; Conlon, Kevin C. ; Keating, Anne ; Waldmann, Thomas A. / Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia. In: Blood. 2013 ; Vol. 121, No. 11. pp. 2029-2037.
@article{aa014dee20ab4822afdee7632a8cff6a,
title = "Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia",
abstract = "Adult T-cell leukemia (ATL) is an aggressive malignancy of CD4+CD25+ lymphocytes caused by human T-cell lymphotropic virus type 1. Currently, there is no accepted curative therapy for ATL. In gene expression profiling, the antiapoptotic protein survivin (BIRC5) demonstrated a striking increase in ATL, and its expression was increased in patient ATL cells resistant to the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H). In this study, we investigated the antitumor activity of a small-molecule survivin suppressant YM155 alone and in combination with alemtuzumab in a murine model of human ATL (MET-1). Both YM155 alone and its combination with alemtuzumab demonstrated therapeutic efficacy by lowering serum soluble IL-2Rα (sIL-2Rα) levels (P < .001) and prolonged the survival of tumor-bearing mice (P < .0001). Moreover, the combination of YM155 with alemtuzumab demonstrated markedly additive antitumor activity by significantly lowering serum sIL-2Rα levels and improving the survival of leukemia-bearing mice compared with monotherapy with either YM155 (P < .001) or alemtuzumab (P < .05). More significantly, all mice that received the combination therapy survived and were tumor free >6 months after treatment. Our data support a clinical trial of the combination of YM155 with alemtuzumab in ATL.",
author = "Jing Chen and Pise-Masison, {Cynthia A.} and Shih, {Joanna H.} and Morris, {John C.} and Janik, {John Edward} and Conlon, {Kevin C.} and Anne Keating and Waldmann, {Thomas A.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1182/blood-2012-05-427773",
language = "English (US)",
volume = "121",
pages = "2029--2037",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11",

}

TY - JOUR

T1 - Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia

AU - Chen, Jing

AU - Pise-Masison, Cynthia A.

AU - Shih, Joanna H.

AU - Morris, John C.

AU - Janik, John Edward

AU - Conlon, Kevin C.

AU - Keating, Anne

AU - Waldmann, Thomas A.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Adult T-cell leukemia (ATL) is an aggressive malignancy of CD4+CD25+ lymphocytes caused by human T-cell lymphotropic virus type 1. Currently, there is no accepted curative therapy for ATL. In gene expression profiling, the antiapoptotic protein survivin (BIRC5) demonstrated a striking increase in ATL, and its expression was increased in patient ATL cells resistant to the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H). In this study, we investigated the antitumor activity of a small-molecule survivin suppressant YM155 alone and in combination with alemtuzumab in a murine model of human ATL (MET-1). Both YM155 alone and its combination with alemtuzumab demonstrated therapeutic efficacy by lowering serum soluble IL-2Rα (sIL-2Rα) levels (P < .001) and prolonged the survival of tumor-bearing mice (P < .0001). Moreover, the combination of YM155 with alemtuzumab demonstrated markedly additive antitumor activity by significantly lowering serum sIL-2Rα levels and improving the survival of leukemia-bearing mice compared with monotherapy with either YM155 (P < .001) or alemtuzumab (P < .05). More significantly, all mice that received the combination therapy survived and were tumor free >6 months after treatment. Our data support a clinical trial of the combination of YM155 with alemtuzumab in ATL.

AB - Adult T-cell leukemia (ATL) is an aggressive malignancy of CD4+CD25+ lymphocytes caused by human T-cell lymphotropic virus type 1. Currently, there is no accepted curative therapy for ATL. In gene expression profiling, the antiapoptotic protein survivin (BIRC5) demonstrated a striking increase in ATL, and its expression was increased in patient ATL cells resistant to the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H). In this study, we investigated the antitumor activity of a small-molecule survivin suppressant YM155 alone and in combination with alemtuzumab in a murine model of human ATL (MET-1). Both YM155 alone and its combination with alemtuzumab demonstrated therapeutic efficacy by lowering serum soluble IL-2Rα (sIL-2Rα) levels (P < .001) and prolonged the survival of tumor-bearing mice (P < .0001). Moreover, the combination of YM155 with alemtuzumab demonstrated markedly additive antitumor activity by significantly lowering serum sIL-2Rα levels and improving the survival of leukemia-bearing mice compared with monotherapy with either YM155 (P < .001) or alemtuzumab (P < .05). More significantly, all mice that received the combination therapy survived and were tumor free >6 months after treatment. Our data support a clinical trial of the combination of YM155 with alemtuzumab in ATL.

UR - http://www.scopus.com/inward/record.url?scp=84877610547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877610547&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-05-427773

DO - 10.1182/blood-2012-05-427773

M3 - Article

C2 - 23321252

AN - SCOPUS:84877610547

VL - 121

SP - 2029

EP - 2037

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11

ER -